Roche in Switzerland

Similar documents
Media Release. Roche enters a broad strategic collaboration with Foundation Medicine in the field of molecular information in oncology

Personalised Healthcare Solutions (PHCS) Excellence for your Biomarker-driven Strategies

Margins of pharmaceutical companies are continuing to decline the future lies in new ecosystems

Roche, Roche Molecular Diagnostics and more

Roche to present new data at AAN reinforcing efficacy and safety of newly FDAapproved OCREVUS (ocrelizumab) in two types of multiple sclerosis

Roche in Australia Innovation Leader

BIOTECH IN FRANCE. key info in. points

Roche Diagnostics Establishes Continental SAP Template with ERP on HANA

Annual General Meeting Roche Holding Ltd 14 March 2017

Innovation and Sustainability: An integrated approach

Annual General Meeting Roche Holding Ltd 4 March 2014

Welcome to our 29 th Global GS1 Healthcare Conference. Follow us on Twitter and tweet about the #GS1HCuae

healthcare company, focused on patients needs SANOFI AT A GLANCE

Molecular Partners launches IPO on SIX Swiss Exchange

Company Profile. German-Taiwan Biotech Seminar 6 November 2017

Antibody Discovery at Evotec

Eden Biodesign ebook. Celebrating 10 Years of Success

Investor Update. Roche to present new data from its industry-leading haematology portfolio at the American Society of Hematology 2018 Annual Meeting

1.0 Background to the organisation

Bringing a successful partnership to the next level

Investor Update. FDA grants Breakthrough Therapy Designation for Roche s Hemlibra in haemophilia A without inhibitors. Basel, 17 April 2018

11% of employees are dedicated to R&D. 11 billions IVD market size 3,000 companies 75,000 people employed. 40,000 IVD products

HIGH-TECH INDUSTRIES BIOTECH IN FRANCE KEY INFO IN POINTS

Global In-Vitro Diagnostic Market Report

Innovation in medical devices as response to Europe's healthcare challenges. Industry's viewpoint

Media Release. Basel, 14 June 2018

Media Release. Roche to present new data across a range of blood diseases at the American Society of Hematology (ASH) 2017 Annual Meeting

A European Public-Private Partnership! in Healthcare! Michel Goldman, MD,PhD Executive Director

BOARD PAPER - NHS ENGLAND. Purpose of Paper: To inform the Board of the development of an NHS England Personalised Medicine Strategy.

Overview: The future of medicine is personalised. Severin Schwan, CEO

Media Release. Roche announces positive interim results for emicizumab in phase III study of children with haemophilia A. Basel, 17 April 2017

Global In-Vitro Diagnostics (IVD) Market Report

New Tools for the Enhanced

Drug Discovery insights. Building

Annual General Meeting Roche Holding Ltd 6 March 2012

Valuing Healthcare Biotechnology in Europe: EuropaBio s perspective

PHARMACEUTICALS EXPORT PROMOTION COUNCIL (Set up by Ministry of Commerce, Govt. of India)

Investor Update. Basel, 14 June 2018

cobas p 512 pre-analytical system Adapting to today s needs. Flexible for tomorrow s demand.

Molecular Diagnostics

This is Shire. 68 We have offices in 68 countries Our products are available in more than 100 countries.

Personalized healthcare Getting from promise to reality

Annual General Meeting Roche Holding Ltd

Curriculum vitae. Personal Data Name Ioan Nani. Nationality: Romanian Field of activity: Manufacture of medicines and pharmaceutical products

What is biomedical science?

Vision, aims and strategies. Department of Immunology, Genetics and Pathology Uppsala University

TECHNOLOGIES & SERVICES FOR THERAPEUTIC ANTIBODY DEVELOPMENT

Our people. Employee engagement and talent retention Compensation/benefits Leadership commitments Organisational effectivenesss

COPE. FAQs CORPORATE ONCOLOGY PROGRAM FOR EMPLOYEES

Develop YOUR business in Medicon Valley Dedicated to helping you develop your business, Medicon Valley offers:

Bayer in Switzerland

Novel nuclear medicine to advance patient care

PerkinElmer, Inc. JP Morgan Global Healthcare Conference. Robert Friel, Chairman and CEO January 14, 2015 HUMAN HEALTH ENVIRONMENTAL HEALTH

Annual General Meeting Roche Holding Ltd 13 March 2018

FDA grants Priority Review to Roche s Hemlibra for people with haemophilia A without factor VIII inhibitors

Topic: Genome-Environment Interactions in Inflammatory Skin Disease

cobas p 612 pre-analytical system Adapting to today s needs. Flexible for tomorrow s demand.

Media Release. CHMP recommends EU approval of Roche s Hemlibra for people with severe haemophilia A without factor VIII inhibitors

Rare diseases in the 7th EU Framework Programme for Research and Technological Development

cobas p 512 pre-analytical system Adapting to today s needs. Flexible for tomorrow s demand.

CCTG initiative. patient reported outcomes (including wearables)

The Innovative Medicines Initiative: Building new models of collaborative research across Europe

MOSAIQ. Radiation Oncology Information System. Confidence for you and your patients

Personalized Healthcare Diagnostik und Therapie aus einer Hand

93,734 employees in more than 100 countries. 26 Manufacturing sites in Pharmaceuticals and Diagnostics worldwide

Inaugural Fraunhofer Delaware Technology Summit

India as an Outsourcing Frontier in Biotechnology

Idorsia Company Profile

THE CORPORATE REPUTATION OF PHARMA 2015 THE PERSPECTIVE OF 118 PATIENT GROUPS with an interest in RESPIRATORY CONDTIONS

The NHS approach to personalised medicine in respiratory disease. Professor Sue Chief Scientific Officer for England

Konica Minolta to Acquire Invicro (US)

Investor Update. Roche to present new data across a range of blood diseases at the American Society of Hematology (ASH) 2017 Annual Meeting

Annual General Meeting Roche Holding Ltd 6 March 2012

Partnering & Networks

Universal Biosensors, Inc.

Save the Date April 3-4, 2014

4P-Pharma SAS - Pharmaceuticals & Healthcare - Deals and Alliances Profile.

Cancer Research UK; $500m annual research spend on basic research, drug discovery and clinical development

Adis Journals and Newsletters The premier collection of drug-focused medical journals

Roche s Hemlibra significantly reduced bleeds in phase III study in haemophilia A

Biotech / Life Science Sector

Insight to Gene Techno Science Co.,Ltd

Janssens Discovery Data Integrity program (DDI): A journey over the last 7 years Research Integrity: Position yourself for success!

Phylogica. Harnessing Biodiversity for Peptide Therapies. Life Sciences Showcase, 23 August 2011 Nick Woolf: CFO & VP Corporate Development

Global Sales and Service International. Kevin Haydon EVP and CEO Global Sales and Service International May 31st 2007

EBE White Paper on Personalised Medicine

Isolation, purification, culturing and cryopreservation of primary cells from human samples

Investor Update. F. Hoffmann-La Roche Ltd 4070 Basel Switzerland. Tel Fax

a pioneering & a a vibrant science & technology company

JP Morgan Healthcare Conference

UBS Global Life Sciences Conference

Nanotechnology and Advanced Materials for more effective Healthcare

Level 7 Monash Health Translation Precinct Translational Research Facility Hudson Institute of Medical Research Melbourne Australia

Belgium, a European leader in clinical trials

L A B O R M A R K E T B R I E F I N G S S E R I E S

Transforming Lonza Specialty Ingredients into a Modern Chemicals Business

Coristo Customer Info Day PSM Product Structure Management. Beat Meier / Martin Behnke Roche Mirko Quintern Coristo

the PLATFORM Pipeline in Lyon AREA

Improved analysis of genetic testing could lead to more patients with inherited conditions being successfully diagnosed

FORWARD THINKING HEALTHCARE

Transcription:

Roche in Switzerland

A leader around the world and at home Last year Roche employed some 13,000 employees from over 90 countries in Switzerland. This makes Switzerland one of Roche s three largest locations in the world, along with the United States and Germany. In Switzerland Roche has 10 cancer medications, many of which improve patients chances of survival. Since 2010, seven innovative products and indications from Roche have been approved in the accelerated process by Swissmedic. Roche is a leading global healthcare company with over 88,500 employees working in more than 150 countries. As the world s largest biotech company, Roche develops specialised medications for oncology, immunology, infectious diseases, ophthalmology, and neurosciences. The Diagnostics division portfolio includes state-of-the-art tests and systems for the early recognition, diagnosis, and monitoring of diseases and for clinical decision making (for example, cancer as well as cardiovascular, inflammatory, and infectious diseases). These also include tests for analysing blood, blood donations, and tissues. Roche is also a pioneer in diabetes management. Medications and diagnostics that crucially improve the health, quality of life, and chances of survival for patients are the strategic aim of personalised medicine at Roche. Roche is one of the five most valuable Swiss companies by market capitalisation on the Swiss stock exchange. In the past three years, Roche has invested some 1.25 billion francs in Switzerland, of which around 1 billion were invested in Basel and Kaiseraugst and 250 million in Rotkreuz. Four out of five people with diabetes who use insulin pumps in Switzerland rely on a product from Roche. Numerous alliances and scientific partnerships exist between Roche and academic institutes in Switzerland. Roche is the largest provider of medications for hospitals in its home market. Roche is among the three leading research institutions in Switzerland, with some 3,500 employees in the areas of pharmacological and diagnostics research and development. About one-quarter of Roche s global research and development spending occurs in Switzerland. Since 2000, Roche has conducted more than 100 clinical studies of medications with well over 2,000 patients. Roche is one of the world s largest investors in research and development. In Switzerland alone, last year Roche spent 2.4 billion Swiss francs. Roche is among the largest private employers in Switzerland and, with over 390 trainees in 14 different professions, one of the country s largest providers of vocational training. The descendants of the founder of Roche make up the majority of Roche shareholders. Hardly any other major company in the world has such a stable and strong ownership structure.

F. Hoffmann-La Roche Ltd, Basel Roche Glycart Ltd, Schlieren 8,500 87 130 22 Basel-Stadt Zürich Group and division leadership, Group functions, global functions, and strategic centres for research, development, production, and marketing. Research areas: infectious diseases, central nervous system, ophthalmology, rare diseases. Roche will invest 3 billion Swiss francs in modern research infrastructure, attractive jobs, and the sustainable development of the site over the next 10 years. pred Innovation Center Zurich with various functions, including large-molecule research, oncology, human immunology, and virology. Unique technology for the development of new generations of therapeutic antibodies with increased effectiveness in previously poorly understood clinical conditions. Kaiseraugst site Roche Diagnostics (Switzerland) Ltd, Rotkreuz 1,900 43 170 7 Aargau Zug Central pillar in the global production and logistics network; centre of competence for sterile production as well as Roche s largest and most modern packaging centre; serves some 130 markets annually. Roche will invest more than half a billion Swiss francs over the coming years in four new office buildings and the expansion of the site s infrastructure. A new learning centre will include an optimal infrastructure for trainees and a state-of-the-art training laboratory that will be unique in Switzerland. Swiss organisation for marketing, sales, and service for diagnostic system solutions, reagents, and test strips as well as IT and workflow services. Market: patients, private and hospital laboratories, universities, medical practices, and research institutes in Switzerland. Roche Diagnostics (Switzerland) Ltd helps our customers optimise their success for the benefit of patients by increasing their diagnostics capabilities with our solutions. Roche Pharma (Switzerland) Ltd, Reinach Roche Diagnostics International Ltd, Rotkreuz 150 8 2,200 60 Basel-Land Zug Marketing and sales, clinical research, registration, scientific documentation, and medical information. Aims to realise holistic solutions in various areas of treatment, including prevention, diagnosis, and therapy as well as patient care. One of the main sites for the Diagnostics division; headquarters for Professional Diagnostics and Molecular Diagnostics; Quality Assurance and Registration department; Global Platforms & Support; Global Instruments Operations; headquarters of the EMEA-LATAM (Europe, Middle East, Africa, and Latin America) regional organisation. New office building (400 workspaces across 12,000 m 2 ).

Engagement Roche supports the Roche n Jazz concerts at the Tin guely Museum in cooperation with the Bird s Eye jazz club in Basel. On its 100th anniversary in 1996, Roche donated the Tin guely Museum to the city of Basel, and since then it has financed the museum s entire operations. With Roche Commissions, Roche spon sors compositions by contemporary composers as part of the Lucerne Festival. Roche supports Schweizer Jugend forscht as well as SimplyScience and the Faszination Technik programme by the Zug Chamber of Commerce. Roche is deeply involved in promoting science and young talent with programmes such as the Roche Postdoc Fellowship and the Genetics Education Program. Roche Children s Walk: sponsored walk in partnership with ECPP and UNICEF Switzerland. Employees collect donations for children in need in countries such as Malawi. Roche matches the collected donations.

Contact F. Hoffmann-La Roche AG Grenzacherstrasse 124 CH-4070 Basel Tel. +41 61 688 11 11 www.roche.ch/en/standorte/basel-hq.htm Roche Glycart AG Wagistrasse 18 CH-8952 Schlieren Tel. +41 44 755 61 61 www.roche.ch/en/standorte/schlieren.htm Roche Kaiseraugst Wurmisweg CH-4303 Kaiseraugst Tel. +41 61 688 11 11 www.roche.ch/en/standorte/basel-hq.htm Roche Diagnostics (Schweiz) AG Industriestrasse 7 CH-6343 Rotkreuz Tel. +41 41 799 61 00 www.roche-diagnostics.ch Roche Pharma (Schweiz) AG Schönmattstrasse 2 CH-4153 Reinach Tel. +41 61 715 41 11 www.roche-pharma.ch Roche Diagnostics International AG Forrenstrasse 2 CH-6343 Rotkreuz Tel. +41 41 799 22 44 www.roche.ch/en/standorte/rotkreuz.htm 2015 All trademarks are legally protected.